Affiliation:
1. Division of Inflammation Research, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan
Abstract
Abstract
Nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) is an intracellular innate immune receptor that recognizes a diverse range of stimuli derived from pathogens, damaged or dead cells, and irritants. NLRP3 activation causes the assembly of a large multiprotein complex termed the NLRP3 inflammasome, and leads to the secretion of bioactive interleukin (IL)-1β and IL-18 as well as the induction of inflammatory cell death termed pyroptosis. Accumulating evidence indicates that NLRP3 inflammasome plays a key role in the pathogenesis of sterile inflammatory diseases, including atherosclerosis and other vascular diseases. Indeed, the results of the Canakinumab Anti-inflammatory Thrombosis Outcome Study trial demonstrated that IL-1β-mediated inflammation plays an important role in atherothrombotic events and suggested that NLRP3 inflammasome is a key driver of atherosclerosis. In this review, we will summarize the current state of knowledge regarding the role of NLRP3 inflammasome in vascular diseases, in particular in atherosclerosis, vascular injury, aortic aneurysm, and Kawasaki disease vasculitis, and discuss NLRP3 inflammasome as a therapeutic target for these disorders.
Funder
Japan Society for the Promotion of Science
Grants-in-Aid for Scientific Research
Private University Research Branding Project
Agency for Medical Research and Development-Core Research for Evolutional Science and Technology
Publisher
Oxford University Press (OUP)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine,Physiology
Reference162 articles.
1. Inflammation as a cardiovascular risk factor;Willerson;Circulation,2004
2. Inflammation and cardiovascular diseases: lessons from seminal clinical trials;Liberale;Cardiovasc Res,2020
3. Inflammatory markers and outcomes in cardiovascular disease;Kritharides;PLoS Med,2009
4. Antiinflammatory therapy with canakinumab for atherosclerotic disease;Ridker;N Engl J Med,2017
5. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease;Abbate;Circ Res,2020
Cited by
113 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献